Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

CTR Vegivinti, KW Evanson, H Lyons, I Akosman… - BMC Infectious …, 2022 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …

Molnupiravir and its antiviral activity against COVID-19

L Tian, Z Pang, M Li, F Lou, X An, S Zhu… - Frontiers in …, 2022 - frontiersin.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Pharmacological treatment of COVID-19: an opinion paper

A García-Lledó, J Gómez-Pavón… - Revista Española …, 2021 - pmc.ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …

Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review

WF Qomara, DN Primanissa, SH Amalia… - … journal of general …, 2021 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel
strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID …

Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies

WH Faour, A Choaib, E Issa, FE Choueiry… - Inflammation …, 2022 - Springer
The COVID-19 pandemic created a worldwide debilitating health crisis with the entire
humanity suffering from the deleterious effects associated with the high infectivity and …

Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials

C Zhang, H Jin, YF Wen, G Yin - Frontiers in Public Health, 2021 - frontiersin.org
Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …

[HTML][HTML] Emerging SARS-CoV-2 variants: Why, how, and what's next?

Y Chen, Q Liu, L Zhou, Y Zhou, H Yan, K Lan - Cell Insight, 2022 - Elsevier
The emergence of the SARS-CoV-2 Omicron variant poses a striking threat to human
society. More than 30 mutations in the Spike protein of the Omicron variant severely …

The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies

DT Hung, S Ghula, JMA Aziz, AM Makram… - International Journal of …, 2022 - Elsevier
Objectives This study aimed to evaluate the efficacy and adverse events of favipiravir in
patients with COVID-19. Methods Our protocol was registered on PROSPERO …

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2× 2 factorial placebo-controlled trial of early antiviral therapy in COVID …

DM Lowe, LAK Brown, K Chowdhury, S Davey… - PLoS …, 2022 - journals.plos.org
Background Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19)
but currently available agents are expensive. Favipiravir is routinely used in many countries …

Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future

DM Hertanto, BS Wiratama, H Sutanto… - Journal of …, 2021 - Taylor & Francis
In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …